First Flight Venture Center

AthemBio is a biotechnology company focused on addressing significant challenges in bioprocessing, particularly in the manufacturing of biologics. The company develops innovative technologies and solutions aimed at combating pandemics and emerging threats from novel pathogens. AthemBio's offerings include advanced medical devices and bioprocessing systems designed to help healthcare institutions isolate and purify therapeutic antibodies. These capabilities are essential for treating COVID-19 and other pathogenic outbreaks, positioning AthemBio as a key player in the fight against infectious diseases.

Regennova is a biotechnology company dedicated to developing innovative therapeutics for inflammatory diseases and neurological disorders. The company focuses on addressing conditions such as cerebral stroke, traumatic brain injury, and Alzheimer's disease. Additionally, Regennova aims to combat sepsis and septic shock, particularly in cases involving multi-drug resistant bacteria. By pursuing novel treatment options, Regennova seeks to provide effective solutions for tau-mediated diseases, improving patient outcomes in these critical areas of healthcare.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

Sensible Biotechnologies is developing a cell-based design, optimization, and manufacturing platform to enable next-generation messenger RNA medicines. The platform integrates cell engineering, computational biology, and precision fermentation to create and manufacture high-quality mRNA constructs with reduced immunogenicity. In particular, it focuses on optimizing the production of vaccinia capping enzymes to improve the stability and translation of therapeutic mRNA, supporting the creation of vaccines and medicines that are more effective and accessible. The approach aims to streamline development from design to production, reducing time and cost in bringing mRNA therapies to patients.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

QUANTiSCOPE improves drug discovery by providing automated image analysis tools that are simple to integrate into research processes.

AVECRIS specializes in advanced biological delivery systems for genetic therapies. Its platform extends the capabilities of mRNA/RNA approaches, offering stable, long-lasting protein expression, non-integrating constructs unlikely to elicit innate immunity, and a redosable, titratable system suitable for mitochondrial gene therapy.

QATCH Technologies is a developer of innovative tools aimed at enhancing the biopharmaceutical industry. The company specializes in a proprietary pre-screening tool that utilizes advanced microfluidic sensor technology combined with acoustics. This technology allows for the precise processing of nanoliters of liquid, enabling researchers to assess the injectability and manufacturability of biopharmaceutical formulations at an early stage. By measuring viscosity and identifying potential manufacturing issues related to formulation, QATCH Technologies empowers biopharma researchers to select optimal injectable molecules while minimizing liquid volume requirements.

Jurata Thin Film develops thin films that enhance the storage and delivery of vaccines and biologics. Its technology enables long-term stability at room temperature or higher, eliminating the need for refrigeration and improving global accessibility to these vital therapies.

PrecNA specializes in manufacturing customizable equipment for the production of lipid nanoparticle formulations using advanced microfluidic technology.